

Remarks

The claims have been amended by canceling claims 1-11 and adding new claims 12-14. New independent claim 12 is supported by, for example, original claims 6 and 7; and page 2, line 34 to page 3, line 11; and page 6, lines 17-31. New dependent claims 13 and 14 are rewording of original claim 4. Accordingly, the amendments are not new matter.

The claims have been amended to be no longer coextensive in scope to U.S. Patent No. 6,500,804 or copending Application No. 10/910,176. Accordingly, Applicants respectfully request withdrawal of the rejections and request issuance of a Notice of Allowability.

The Commissioner is hereby authorized to charge any fees due in connection herewith to Deposit Account No. 50-2783.

Respectfully submitted,

Dated: June 5, 2006


Mr. Shu M. Lee
Attorney for Applicants
CUSTOMER NUMBER 38724
Registration No. 41,147
OSI Pharmaceuticals, Inc.
41 Pinelawn Road
Melville, New York 11747
Telephone: (631) 962-2056
Facsimile: (631) 845-0582